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Abstract
Background: Lafora disease (LD) is a rare, lethal, progressive myoclonus epilepsy for which no targeted therapy is
currently available. Studies on a mouse model of LD showed a good response to metformin, a drug with a well
known neuroprotective effect. For this reason, in 2016, the European Medicines Agency granted orphan designation to
metformin for the treatment of LD. However, no clinical data is available thus far.
Methods: We retrospectively collected data on LD patients treated with metformin referred to three Italian epilepsy
centres.
Results: Twelve patients with genetically confirmed LD (6 EPM2A, 6 NHLRC1) at middle/late stages of disease were
treated with add-on metformin for a mean period of 18months (range: 6–36). Metformin was titrated to a mean
maintenance dose of 1167mg/day (range: 500–2000mg). In four patients dosing was limited by gastrointestinal side-
effects. No serious adverse events occurred. Three patients had a clinical response, which was temporary in two,
characterized by a reduction of seizure frequency and global clinical improvement.
Conclusions: Metformin was overall safe in our small cohort of LD patients. Even though the clinical outcome was
poor, this may be related to the advanced stage of disease in our cases and we cannot exclude a role of metformin in
slowing down LD progression. Therefore, on the grounds of the preclinical data, we believe that treatment with
metformin may be attempted as early as possible in the course of LD.
Keywords: Metformin, Lafora disease, Progressive myoclonus epilepsy, EPM2A, EPM2B, NHLRC1
Introduction
Lafora disease (LD) is a lethal, autosomal recessive, pro-
gressive myoclonus epilepsy. LD is caused by mutations in
EPM2A or NHLRC1, encoding laforin and malin, respect-
ively. With loss of function of either, structurally abnormal
glycogen becomes insoluble and accumulates as Lafora
bodies, responsible for disease progression [1]. Disruptions
in cell homeostasis such as proteasomal dysfunction, oxida-
tive stress, autophagy impairment, and mitochondrial dys-
function, also play a role in the pathophysiology of LD [2].
Symptoms typically begin in adolescence, and death
commonly occurs within 10 years of onset. Antiepileptic
drugs (AED) are partially effective on myoclonus and sei-
zures but don’t have a major influence on the progression
of cognitive and behavioural symptoms [3]. Despite the
presence of new promising treatment strategies, no
targeted therapy for LD in humans is currently available
[3]. Metformin is an activator of AMP-induced kinase
(AMPK) and is the most commonly prescribed drug for
type 2 diabetes mellitus [4, 5]. AMPK is a key cellular
energy sensor that, once activated by falling energy status,
responds by activating catabolic pathways and inhibiting
anabolic ones, such as glycogen synthesis [6]. Interestingly,
the reduction of brain glycogen synthesis is one of the most
promising therapeutic avenues for LD [3]. Moreover,
through the activation of AMPK, metformin promotes
autophagy and can also prevent brain mitochondrial dys-
function, decrease oxidative stress, and inhibit apoptotic
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cascade by preventing the permeability transition pore
opening [7–11]. Through these and possibly other mecha-
nisms, metformin acts as a neuroprotective agent in differ-
ent neurodegenerative diseases [11–14]. It was also shown
to facilitate seizure termination in mice [15]. A mouse
model of LD treated with metformin showed amelioration
of neuropathological symptoms, reduced seizure suscepti-
bility and decreased accumulation of Lafora bodies [16,
17]. In 2016, the European Medicines Agency granted or-
phan designation to metformin for the treatment of LD
(decision number EU/3/16/1803). However, no clinical data
on treatment with metformin in LD is available thus far
[3], also because of its extreme rarity. Here, we present a
case series of LD patients treated with metformin.
Methods
We collected data from three Italian epilepsy centres in
which treatment with add-on metformin was proposed to
all referred patients with genetically confirmed LD,
irrespective of the stage of disease progression. Liver and
kidney dysfunction, which may predispose to the develop-
ment of lactic acidosis in diabetic patients treated with
metformin, were excluded by standard laboratory testing in
all patients. The stage of disease progression was assessed
using a disability scale based on the residual motor and
mental functions, daily living and social abilities [18]. Met-
formin was titrated to an individual target dose starting
from 500mg/die, depending on tolerability and clinical
response. The latter was assessed considering the
frequency of generalized tonic-clonic seizures, myoclonus
severity, as well as the clinical, patient, and caregiver global
impression.
Patients were evaluated at least at monthly frequency,
either on an outpatient basis, during hospitalisation, or
using telephone interviews with caregivers and home-made
videos. If patients were hospitalised in institutes other than
the three participating centres, data on their clinical status
were obtained through the referring clinicians.
Results
Study population and treatment details
Twelve consecutive Italian patients with genetically con-
firmed LD were screened for contraindications and were
consequently treated with add-on metformin. The first
patient commenced treatment in February 2016. Last
follow-up visit was in March 2019. Two cases were pre-
viously reported [19]. Clinical features of the subjects
and treatment details are summarized in Table 1.
Of the 12 patients, 7 were female. Mean age at disease
onset was 13 years. Metformin was introduced at middle/
late stages of disease, after a mean of 8 years from onset.
Treatment duration ranged from 6 to 36months (mean =
18 months). Metformin was titrated to an individual target
dose depending on tolerability and clinical response, up to
3000mg/day. The mean maintenance dose was 1167mg/
day (range: 500-2000mg).
Clinical outcome
In 9 out of 12 patients, metformin did not produce any
relevant clinical benefit. In the remainder, we observed a
clinical improvement. When metformin was introduced,
patient 1 was staying in a long-term care facility in a vegeta-
tive state, had subcontinuous myoclonic jerks, no spontan-
eous motor activity and weekly generalized myoclonic
seizures, lasting more than 5min if not treated with benzo-
diazepines. During the 6 months of metformine therapy,
the patient showed reduction of myoclonic seizures
frequency with consequent reduction of benzodiazepine
rescue medications, as well as the appearance of eye
response to vocal stimuli. A further clinical deterioration
followed, and the patient died of tracheostomy-related late
bleeding. Patient 2 had a transitory clinical response, lasted
approximately 6 months, characterized by improvement in
behaviour and cognition and seizure-freedom. However,
perampanel (up to 6mg/day) was introduced at the same
time as metformin because of the rapidly progressing
clinical deterioration, and may therefore be responsible for
the clinical improvement. Patient 10 had a long disease
progression and at time of metformin introduction was
bedridden, severely cognitively impaired, had subcontinous
myoclonic jerks and approximately one generalized tonic
clonic seizure (GTCS) per month. Treatment resulted in a
reduction of myoclonus intensity, freedom from GTCS and
an improved responsiveness, maintained for the 36months
of follow-up, during which concomitant AED regimen was
not modified.
Adverse events
Adverse events (AEs) were reported in six patients. The
most common was diarrhoea (n = 4), which subsided in all
patients after dose adjustment. Patient 4 reported asthenia
with metformin at 1000mg, not clearly related to treat-
ment. Patient 6 had muscle cramps and elevated CPK,
resolved after discontinuation. Patient 3 was given a max-
imal dose of 500mg because pre-treatment basal gly-
caemia was at the lower normal limit. In this case,
metformin was suspended after 12months because there
was no clinical benefit. No serious AEs were reported in
any patient.
Discussion
Safety and tolerability
To the best of our knowledge, this is the first documenta-
tion of metformin use in humans with LD. None of our
patients experienced serious AEs. In one case, reversible
side effects brought to discontinuation. Gastrointestinal
side effects are a well known metformin AE, are usually
transient and subside once the dose is adjusted or when
Bisulli et al. Orphanet Journal of Rare Diseases          (2019) 14:149 Page 2 of 5
Ta
b
le
1
C
lin
ic
al
fe
at
ur
es
an
d
tr
ea
tm
en
t
de
ta
ils
C
lin
ic
al
Fe
at
ur
es
Pr
e-
Tr
ea
tm
en
t
A
ss
es
sm
en
t
M
et
fo
rm
in
Tr
ea
tm
en
t
Pt
A
ge
(y
),
Se
x
O
ns
et
ag
e
(y
)
M
ut
at
io
na
D
is
ea
se
du
ra
tio
n
(y
)
C
on
co
m
ita
nt
A
ED
s
N
o.
G
TC
S
(la
st
28
da
ys
)
M
yo
cl
on
us
b
D
is
ab
ili
ty
sc
al
ec
M
ax
im
al
do
se
(m
g)
,
ad
ju
st
ed
do
se
(m
g)
O
ut
co
m
e
D
ur
at
io
n
(m
on
th
s)
A
dv
er
se
ev
en
ts
1
17
d
,F
13
EP
M
2A
:c
.4
91
T
>
G
(p
.Il
e1
64
Se
r),
c.
53
9
T
>
C
(p
.L
eu
18
0P
ro
)
4
VP
A
,Z
N
S,
PB
0e
+
+
+
4
30
00
,1
50
0
M
ild
im
pr
ov
em
en
t
(s
ee
te
xt
)
6
D
ia
rr
ho
ea
2
21
,M
16
N
H
RL
C1
:c
.4
36
G
>
A
(p
.A
sp
14
6A
sn
),
c.
11
33
T
>
C
(p
.L
eu
37
8P
ro
)
4
VP
A
,L
EV
,P
ER
f ,
C
N
Z,
C
LB
18
+
3
20
00
,1
00
0
Se
iz
ur
e-
fre
ed
om
,
im
pr
ov
ed
co
gn
iti
on
,
la
st
ed
fo
r
6
m
on
th
s
9
D
ia
rr
ho
ea
3g
25
,F
13
EP
M
2A
:c
.2
43
_2
46
de
l
(p
.A
sp
82
A
rg
fs
*7
)
10
VP
A
,L
EV
,Z
N
S,
PB
,C
N
Z
3
+
+
+
4
50
0,
50
0
D
is
ea
se
pr
og
re
ss
io
n
12
h
N
on
e
4g
19
,F
10
N
H
LR
C1
:c
.2
05
C
>
G
(p
.P
ro
69
A
la
);
c.
82
6_
82
9d
up
(p
.A
la
27
7A
sp
fs
*2
3)
7
VP
A
,L
EV
,Z
N
S,
C
N
Z
6
+
+
+
4
10
00
,5
00
D
is
ea
se
pr
og
re
ss
io
n
24
A
st
he
ni
a
5
17
,F
13
N
H
LR
C1
:c
.2
05
C
>
G
(p
.P
ro
69
A
la
)
3
VP
A
,L
EV
,P
ER
,
C
N
Z
8
+
+
+
4
20
00
,2
00
0
D
is
ea
se
pr
og
re
ss
io
n
13
N
on
e
6
23
,M
14
EP
M
2A
:c
.7
21
C
>
T
(p
.A
rg
24
1*
)
7
LE
V,
TP
M
,Z
N
S
7
+
+
+
4
20
00
,2
00
0
D
is
ea
se
pr
og
re
ss
io
n
9h
El
ev
at
ed
C
PK
,
m
us
cl
e
cr
am
ps
7
23
,M
10
EP
M
2A
:c
.7
21
C
>
T
(p
.A
rg
24
1*
)
11
VP
A
,P
B,
PH
T,
PE
R,
C
N
Z
11
+
+
+
3
20
00
,2
00
0
D
is
ea
se
pr
og
re
ss
io
n
28
N
on
e
8
18
,M
14
N
H
LR
C1
:c
.9
92
de
l(
p.
G
ly
33
1G
lu
fs
*3
)
2
VP
A
,L
EV
,P
ER
2
+
+
2
17
00
,5
00
D
is
ea
se
pr
og
re
ss
io
n
26
D
ia
rr
ho
ea
9
22
,F
13
N
H
LR
C1
:c
.9
92
de
l(
p.
G
ly
33
1G
lu
fs
*3
)
7
VP
A
,Z
N
S,
PE
R
3
+
+
+
4
17
00
,5
00
D
is
ea
se
pr
og
re
ss
io
n
26
D
ia
rr
ho
ea
10
50
,F
18
EP
M
2A
:c
.7
21
C
>
T
(p
.A
rg
24
1*
),
c.
83
5G
>
A
(p
.G
ly
27
9S
er
)
29
VP
A
,L
EV
,Z
N
S,
C
N
Z
1
+
+
+
4
10
00
,1
00
0
M
ild
im
pr
ov
em
en
t
(s
ee
te
xt
)
36
N
on
e
11
19
,F
11
EP
M
2A
:c
.3
23
G
>
T
(p
.A
rg
10
8L
eu
)
7
VP
A
,P
B,
PE
R,
C
N
Z
0.
5
+
+
+
4
10
00
,1
00
0
D
is
ea
se
pr
og
re
ss
io
n
12
N
on
e
12
18
,M
13
N
H
LR
C1
:c
.4
36
G
>
A
(p
.A
sp
14
6A
sn
),
c.
11
33
T
>
C
(p
.L
eu
37
8P
ro
)
4
VP
A
,L
EV
,Z
N
S,
PB
3
+
+
3
15
00
,1
50
0
D
is
ea
se
pr
og
re
ss
io
n
12
N
on
e
Le
ge
nd
:A
ED
an
tie
pi
le
pt
ic
dr
ug
,C
LB
cl
ob
az
am
,C
N
Z
cl
on
az
ep
am
,G
TC
S
ge
ne
ra
liz
ed
to
ni
c-
cl
on
ic
se
iz
ur
es
,L
D
La
fo
ra
di
se
as
e,
LE
V
le
ve
tir
ac
et
am
,P
B
ph
en
ob
ar
bi
ta
l,
PE
R
pe
ra
m
pa
ne
l,
PH
T
ph
en
yt
oi
n,
TP
M
to
pi
ra
m
at
e,
VP
A
va
lp
ro
at
e,
ZN
S
zo
ni
sa
m
id
e
a W
he
n
on
ly
on
e
va
ria
nt
is
in
di
ca
te
d,
th
is
is
in
te
nd
ed
as
ho
m
oz
yg
ou
s.
EP
M
2A
Re
fS
eq
ID
:N
M
_0
05
67
0.
4;
N
H
LR
C1
Re
fS
eq
:N
M
_1
98
58
6.
2
b
M
yo
cl
on
us
se
ve
rit
y:
+
,m
ild
m
yo
cl
on
us
,i
.e
.d
oe
s
no
t
in
te
rf
er
e
w
ith
ac
tiv
iti
es
of
da
ily
liv
in
g;
+
+
,m
od
er
at
e
m
yo
cl
on
us
,i
.e
.i
nt
er
fe
re
s
w
ith
ac
tiv
iti
es
of
da
ily
liv
in
g
bu
t
no
t
w
ith
de
am
bu
la
tio
n;
+
+
+
,s
ev
er
e
m
yo
cl
on
us
,i
.e
.
in
te
rf
er
es
w
ith
de
am
bu
la
tio
n
c D
is
ab
ili
ty
sc
al
e
de
ve
lo
pe
d
by
Fr
an
ce
sc
he
tt
ie
t
al
.[
18
]:
1,
m
ild
co
gn
iti
ve
an
d
m
ot
or
im
pa
irm
en
t,
pr
es
er
ve
d
da
ily
liv
in
g
ac
tiv
iti
es
,a
nd
so
ci
al
in
te
ra
ct
io
n;
2,
m
od
er
at
e
m
en
ta
ld
ec
lin
e,
lim
ita
tio
ns
in
m
ot
or
ac
tiv
iti
es
an
d
lim
ite
d
so
ci
al
in
te
ra
ct
io
n;
3,
se
ve
re
m
en
ta
la
nd
m
ot
or
im
pa
irm
en
t,
ne
ed
in
g
he
lp
in
w
al
ki
ng
an
d
re
gu
la
r
as
si
st
an
ce
in
da
ily
ac
tiv
ity
,a
nd
po
or
so
ci
al
in
te
ra
ct
io
n;
4,
pa
tie
nt
w
ee
lc
ha
ir-
bo
un
d
or
be
dr
id
de
n,
an
d
no
si
gn
ifi
ca
nt
da
ily
liv
in
g
ac
tiv
iti
es
or
so
ci
al
in
te
ra
ct
io
n
d
de
ce
as
ed
e t
he
pa
tie
nt
di
d
no
t
pr
es
en
t
an
y
G
TC
S
bu
t
ha
d
4
pr
ol
on
ge
d
m
yo
cl
on
ic
se
iz
ur
es
in
28
da
ys
re
qu
iri
ng
be
nz
od
ia
ze
pi
ne
re
sc
ue
m
ed
ic
at
io
ns
f p
er
am
pa
ne
lw
as
in
tr
od
uc
ed
at
th
e
sa
m
e
tim
e
as
m
et
fo
rm
in
g
pr
ev
io
us
ly
pu
bl
is
he
d
in
Re
f.
[1
9]
h
su
sp
en
de
d
Bisulli et al. Orphanet Journal of Rare Diseases          (2019) 14:149 Page 3 of 5
administered with meals [4]. Therefore, metformin was
overall well tolerated and safe in our small cohort of LD
subjects.
Efficacy and study limitations
Of twelve treated patients, three had a clinical response,
which was temporary in two. However, it was difficult to
assess the role played by metformin in patient 2, who
was simultaneously started on perampanel. Even though
the disease eventually progressed in all treated patients
but one with end-stage disease, we cannot exclude that
metformin may have the potential to slow down LD pro-
gression, as no prospective study on LD natural history
is available for comparison. The considerable mean delay
of 8 years between disease onset and metformin intro-
duction may be a potential reason for its apparent low
efficacy. It is likely that the mechanisms by which met-
formin may ameliorate disease course in LD, i.e. inhib-
ition of glycogen synthesis, autophagy promotion,
reduction of oxidative stress, maintenance of mitochon-
drial capacities, and inhibition of apoptosis, might be
more incisive if treatment is commenced soon after dis-
ease onset. Theoretically, the neuroprotective action of
metformin would be even more pronounced if treatment
is started in the pre-symptomatic phase in genetically
diagnosed siblings of LD patients, in whom neuronal
degeneration has not been established yet. Indeed, in the
pre-clinical studies in which the efficacy of metformin
treatment in a mouse model of LD was established, the
drug was administered when the mice were 3 months
old, at the beginning of their neurological impairment
[16, 17].
We acknowledge the methodological limitations of our
study, which was retrospective, not randomized, not con-
trolled, and involved a small number of subjects. These
limitations are, however, intrinsically related to the rarity
of LD, to the lack of effective alternative therapies and to
the overall safety of metformin, which brought us to offer
this opportunity to all eligible patients.
Conclusions
Metformin was overall safe in our small cohort of LD
patients at middle/late stages of disease. Even though
the clinical outcome was poor, this may be related to the
relatively advanced stage of disease in our cohort and we
cannot exclude a role of metformin in slowing down LD
progression. Therefore, on the grounds of the preclinical
data, we believe that treatment with metformin may
be attempted as early as possible in the course of LD.
Efficacy of metformin in LD should be further evalu-
ated in randomized controlled trials involving larger
cohorts of patients.
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